PALAU PHARMA

Local Time
Last Revised
06.11.2012

Latest News

07.30.2012Palau Pharma signs an exclusive option agreement with Sensorion Pharmaceuticals for the development of Palau´s histamine-4 receptor antagonist, UR-63325, for the treatment of vestibular disorders

06.11.2012Palau Pharma sells UR-65318, an investigational histamine-4 receptor antagonist for the treatment of a dermatologic condition, to a leading U.S., NYSE-listed pharmaceutical company

03.30.2012Palau Pharma reports positive Phase IIb clinical results on its oral antifungal albaconazole, indicated for the oral treatment of onychomycosis, at the Annual Meeting of the American Academy of Dermatology

02.26.2012Palau Pharma doubles its revenues and forecasts profitability in 2012

Corporate Information

Meet Us At

15May

18June

12November

BioEquity Europe

May 15-16, 2012

Frankfurt
Germany